Drugs / intravenous immune globulin
intravenous immune globulin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02287064 | Apr 2015 → Dec 2016 | cerebellar ataxia | University of South Florida | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03992482 | May → Aug 2019 | dry eye syndrome | Sandeep Jain, MD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04432324 | Jun 2020 → Mar 2021 | COVID-19 | Grifols, S.A. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02728752 | Feb 2017 → Nov 2019 | dermatomyositis | Octapharma | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00586716 | Nov 2004 → Sep 2009 | end stage renal failure | Loma Linda University | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04033276 Comparator | Jan 2019 → Dec 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02525172 Background | Aug 2015 → Jul 2020 | glycogen storage disease II | National Taiwan University Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-01-29 | Takeda | Takeda’s GAMMAGARD LIQUID ® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) takeda.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous Immune Globulin | “BACKGROUND: Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.” PMID 36198179 ↗ Oct 2022 |
| Known as | GAMMAGARD LIQUID | “IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter.” NCT02287064 ↗ |
| Known as | intravenous immunoglobulin | “The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM).” PMID 39918968 ↗ Jun 2025 |
| Known as | IVIG | “The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM).” PMID 39918968 ↗ Jun 20252“Intravenous Immune Globulin (IVIG)” NCT02287064 ↗ “Intravenous Immunoglobulin (IVIG)” NCT03992482 ↗ |
| Known as | Octagam 10% | “IVIg (Octagam 10%; Octapharma AG)” PMID 38233885 ↗ Jan 2024 |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIg)” PMID 40616720 ↗ Jul 2025 |
| Route | Intravenous | “intravenous immune globulin is administered to patients” NCT00586716 ↗ |